A few days ago, Medtronic’s new drug-coated balloon IN.PACT AV was approved by the US FDA. The balloon is specifically designed to help clear the intravenous access for patients undergoing dialysis treatment.

Headline bacteria:  The gospel for dialysis patients is here.

【Dingxiangyuan Insight Database】The first domestic PD-L1 monoclonal antibody will be approved soon

On November 24, the domestic listing application of AstraZeneca’s PD-L1 Durvalumab injection (Imfinzi) was under “ approval ” status ( acceptance number: JXSS1800040/JXSS1800041 ), and it is expected to be approved soon as the first domestically listed PD -L1 monoclonal antibody for the treatment of inoperable stage III non-small cell lung cancer.

Toutiao bacteria: AZ is angry.

[WuXi AppTec] For the first time in ten years to improve OS for patients with liver cancer, Tecentriq combination is superior to first-line standard therapies

A few days ago, Roche announced the PD-L1 antibody Tecentriq (atezolizumab, atezolizumab) combined with Avastin (bevacizumab, bevacizumab) combination therapy, in the treatment of unresectable hepatocytes that have not previously received systemic therapy Positive results were obtained in the phase 3 trial IMbrave150 in patients with cancer (HCC).